checkAd

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

Relief Therapeutics Holding SA / Key word(s): Conference
Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

12.09.2022 / 07:05 CET/CEST


Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum

Geneva, Switzerland, September 12, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a Swiss, commercial-stage biopharmaceutical company seeking to provide patients therapeutic benefit from selected specialty, rare and ultra-rare diseases with high unmet need, today announced that Jack Weinstein, Chief Financial Officer and Treasurer, will participate in a panel discussion and present a company overview during the 22nd Annual Biotech in Europe Forum, being held September 21-22, 2022, in Basel, Switzerland.

Panel Discussion
Title: Navigating Global Capital Markets in Current Times
Date: Wednesday, September 21, 2022
Time: 1:35 pm CEST

Company Presentation
Date: Wednesday, September 21, 2022
Time: 3:20 pm CEST

Management will host one-on-one meetings during the event. Institutional investors and others, who are registered for the conference, can log into https://sachsevent.com/event/22nd-bef/about to request a meeting with the company.

ABOUT RELIEF
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria ("PKU"). Relief has a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including Urea Cycle Disorders (“UCDs”) and Maple Syrup Urine Disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the FDA. In addition, Relief is commercializing several legacy products via licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com. Follow Relief on LinkedIn.
 
CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
 

Additional features:

File: Press release


End of Media Release


Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1439731

 
End of News EQS News Service

1439731  12.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1439731&application_name=news&site_id=wallstreet

Nachrichtenquelle: EQS Group AG
 |  232   |   |   

Schreibe Deinen Kommentar

Disclaimer

Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum Relief Therapeutics Holding SA / Key word(s): Conference Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum 12.09.2022 / 07:05 CET/CEST Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe …

Nachrichten des Autors

242 Leser
107 Leser
43 Leser
740 Leser
389 Leser
377 Leser
368 Leser
359 Leser
359 Leser
355 Leser
345 Leser
327 Leser
326 Leser
1029 Leser
740 Leser
739 Leser
708 Leser
552 Leser
495 Leser
442 Leser
441 Leser
430 Leser
423 Leser
2320 Leser
2237 Leser
2227 Leser
2225 Leser
2200 Leser
2108 Leser
1848 Leser
1803 Leser
1693 Leser
1629 Leser